Diamant Asset Management Inc. Has $109.34 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Diamant Asset Management dramatically increased its Johnson & Johnson stake in the first quarter, buying 4.45 million additional shares and bringing its total holdings to 4.47 million shares worth about $109.3 million.
• Johnson & Johnson reported better-than-expected Q1 earnings, with EPS of $2.70 versus $2.68 expected and revenue of $24.06 billion, up 9.9% year over year. The company also raised its quarterly dividend to $1.34 per share.
• Analyst sentiment remains positive, with multiple firms raising price targets and the stock carrying a Moderate Buy consensus. The article also notes supportive catalysts like a favorable talc lawsuit result and a positive European regulatory opinion for expanded Tecvayli use.

Diamant Asset Management Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 24,436.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,473,008 shares of the company's stock after purchasing an additional 4,454,778 shares during the quarter. Diamant Asset Management Inc. owned approximately 0.19% of Johnson & Johnson worth $109,338,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of JNJ. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the period. State Street Corp lifted its stake in shares of Johnson & Johnson by 1.3% in the fourth quarter. State Street Corp now owns 133,869,843 shares of the company's stock worth $27,704,364,000 after acquiring an additional 1,663,782 shares during the period. Auto Owners Insurance Co boosted its holdings in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Geode Capital Management LLC increased its position in Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock valued at $11,967,947,000 after purchasing an additional 1,738,292 shares during the period. Finally, Norges Bank bought a new position in Johnson & Johnson during the 4th quarter worth approximately $6,924,523,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $254.24 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a twelve month low of $152.81 and a twelve month high of $259.90. The company has a fifty day moving average of $231.79 and a 200-day moving average of $230.37. The firm has a market capitalization of $612.01 billion, a P/E ratio of 29.39, a P/E/G ratio of 2.53 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson's revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio (DPR) is 61.97%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson won a favorable jury outcome in a talc-related lawsuit, reducing some overhang from long-running legal risk tied to allegations that its products caused cancer. Article: Johnson & Johnson (JNJ) Beats Lawsuit Alleging that Talc caused Three Women’s Cancer
• Positive Sentiment: European regulators gave a positive CHMP opinion for expanded use of J&J’s Tecvayli in multiple myeloma, reinforcing confidence in the company’s oncology pipeline and future revenue growth. Article: J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug Tecvayli
• Positive Sentiment: The stock hit a new 52-week high and was described as breaking out past a buy point, suggesting strong investor demand and continued momentum in the shares. Article: Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
• Positive Sentiment: Analyst and media coverage continues to highlight J&J as a dividend and healthcare leader, which can keep income-focused investors interested in the name. Article: Johnson & Johnson NYSE: JNJ Healthcare Rally Lifts Dividend Appeal
• Neutral Sentiment: Several articles focused on J&J’s recent rally and whether the stock still offers value after a strong run, which suggests investors are weighing upside potential against a rich valuation. Article: Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left
• Neutral Sentiment: The company was also noted as a trending stock and a passive-income favorite, reflecting sustained attention rather than a new fundamental catalyst. Article: Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: After six straight sessions of gains, J&J snapped its winning streak, indicating some short-term profit-taking as investors lock in recent gains. Article: Johnson & Johnson snaps six straight sessions of gains

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price objective on the stock in a research note on Wednesday, May 13th. TD Cowen started coverage on shares of Johnson & Johnson in a research note on Wednesday, April 8th. They set a "buy" rating and a $250.00 target price for the company. Argus upped their price target on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. Citigroup increased their price target on Johnson & Johnson from $274.00 to $285.00 and gave the stock a "buy" rating in a report on Tuesday, April 7th. Finally, Johnson Rice set a $270.00 price objective on Johnson & Johnson in a research report on Friday. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $256.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.